MGNX - MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024
2024-04-05 02:31:21 ET
Summary
- Positive safety update released from phase 2 TAMARACK study, using vobra duo for the treatment of patients with metastatic castration-resistant prostate cancer.
- Updates to interim data from the phase 2 TAMARACK study expected by May 31st of 2024.
- Radiographic progression-free survival data from the phase 2 TAMARACK study, expected by fall of 2024.
- The global prostate cancer market size is estimated to reach $27.51 billion by 2032.
MacroGenics ( MGNX ) is an important biotech to keep an eye on, because it has been able to make remarkable progress on advancing the use of its lead drug vobra duo [vobramitamab duocarmazine] in the ongoing phase 2 TAMARACK study for the treatment of patients with metastatic castration-resistant prostate cancer [mCRPC]. It just announced a key finding that may benefit it when it reports data at two time points later this year. It noted that there was a reduced rate of discontinuation of patients in this TAMARACK study for those who were given lower doses of 2 mg/kg and 2.7 mg/kg of vobra duo respectively. A prior phase 1 study, using a higher dose of this drug [3 mg/kg] saw a higher rate of discontinuations. Why should investors be concerned with this latest news release? That's because there are two major milestones ahead as it relates to this specific program....
MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024